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Dementia and the Role of Alzheimer Disease
Jodi Kiessling, RN, BSN
Introduction Underlying Pathophysiology References Cited
• Causes of dementia are: infection 
(encephalitis, meningitis, 
neurosyphilis), normal pressure 
hydrocephalus, chronic subdural 
hematoma, nutritional deficiencies, 
chronic drug or alcohol use, metabolic 
disorders (thyroid abnormalities, 
hepatic encephalopathy, cerebral 
vasculitis, sarcoidosis), tumors, 
medication effects (anticholinergics, 
antihypertensives, antihistamines), 
neurodegenerative disorders 
(Alzheimer disease, dementia with 
Lewy bodies, Frontotemporal 
dementia, Pick disease, Huntington 
disease, Parkinson disease), vascular 
disease (vascular dementia, multi-
infarct, strategic single infarct, 
Binswanger disease, Amyloid 
angiopathy), irreversible infections 
(Creutzfeldt-Jacob disease, 
Postencephalitic dementia, HIV) 
(McCance & Huether, 2019, p. 521).
• Research is still underway to find a 
cause for Alzheimer disease, three 
genes on chromosome 21 have been 
found to play a role in early onset 
familial AD and chromosome 19 has 
been linked in late onset AD (McCance 
& Huether, 2019, p. 521).  The gene 
mutations interrupt the brain’s ability 
to get rid of beta-amyloid proteins, 
which then leads to neurofibrillary 
plaque and tangle development that 
kills neurons.  
• Both the innate and adaptive 
inflammatory processes have been 
found to have implications in AD 
progression. Microglia and astrocytes 
are normally protective and regulatory 
cells of the brain, however, when beta-
amyloid and tau protein accumulate, 
cytokines (i.e. tumor necrosis factor) 
are released and neurons are 
destroyed (Eldik, et al, 2016, p. 100-
102).  
• The blood brain barrier (BBB) plays a 
part in allowing the influx of 
leukocytes when it is damaged by tau 
and beta-amyloid proteins.  BBB 
disruption near the hippocampus, 
which is somewhat normal with aging, 
occurs at a faster rate with AD, and the 
damage to the area around the 
hippocampus translates to memory 
and language deficits (Zenaro, 
Piacentino, & Constatin, 2017, p. 42).  
Alzheimer disease is a progressive 
disease causing cognitive and functional 
decline with the hallmark sign of 
plagues and tangles within the brain.  
Genetics, inflammation, accumulation of 
beta-amyloid protein and breakdown of 
the blood brain barrier are all 
contributing factors in the disease.  
Treatment is not curative and is focused 
on symptom management and 
management of pre-existing chronic 
diseases. 
Dementia is a progressive disease in 
which deterioration of the cerebrum 
causes a disruption in intellect and 
behavior (McCance & Huether, 2019, p. 
520). The incidence of dementia increases 
with age (Larson, 2019, p. 1).   According 
to the World Health Organization (WHO), 
it affects about “50 million people” 
worldwide with close to “10 million new 
cases each year” (WHO, 2019).  The 
diagnosis of dementia is very common in 
hospital and outpatient settings. The most 
common cause is Alzheimer disease (AD) 
consisting of “60% to 80%” of all cases 
(Larson, 2019, p. 3).  
It is a debilitating disease and has 
detrimental effects on the patients, 
caregivers, and family.  As an emergency 
department nurse and a grand-daughter 
of a patient struggling with dementia, this 
has become a topic of interest.
• Inflammatory markers of major 
histocompatibility complex (MHC) 
class II, cyclooxygenase (COX-2), 
monocyte 
chemoattractant/chemotactic protein 
(MCP-1), tumor necrosis factor alpha 
(TNF-a), interleukin beta (IL-b), or IL-
16 can be found near senile plaques 
that are surrounded by microglia and 
astrocytes (Hohsfield & Humpel, 
2015, p. 10). 
• The “neuropathological hallmarks of 
AD are neuronal degeneration, loss of 
synapses, neurofibrillary tangles, 
gliosis, and amyloid-beta 
accumulation in senile plaques” 
(Zenaro, Piacentino & Constatin, 
2017, p. 42).  There is also a loss of 
acetylcholine related to damage to 
cholinergic neurons (McCance & 
Huether, 2019, p. 521). 
• Arteriosclerosis and atherosclerosis 
can lead to infarcts in the brain.  A 
correlation between beta-amyloid 
deposits and decrease in blood flow 
has been discovered  and has been 
theorized to cause cognitive 
dysfunction as well as possibly 
worsen AD.  Because diabetes 
mellitus type II and insulin resistance 
are linked to vascular disease, they 
are risk factors for dementia as well.  
The immune system is attributed to 
inflammation around plaques and 
tangles and impairment of the blood 
brain barrier that lead to neurological 
damage linked to dementia.  The 
blood brain barrier may also be 
disrupted by alterations in lipid 
transport; APOE is involved lipid 
transport and if APOE4 is present, 
that can indicate a genetic precursor 
for AD.  Another factor is lack of 
collateral circulation in the cerebral 
pia during a cerebral vascular 
accident that limits the access of back 
up blood flow (Snyder et al, 2015 p. 2-
4).  
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Conclusion
A 70-year-old female presents to her primary care provider with complaints of disorientation (especially at night), forgetfulness, and 
difficulty completing activities of daily living.  The diagnosis of dementia is established after a thorough history and physical are completed 
as well as the Mini-Mental Status Exam, and other potential causes are ruled out with diagnostic blood work and imaging of the brain.  
Other signs and symptoms might include “a serious loss of at least 2 cognitive functions, such as memory, attention, thinking, or language” 
(Stewart, et al, 2014, p. 275). 
The patient is started on memantine to help slow down the progression of dementia. In a systematic review by Buckley and Salpeter 
(2015) found that cholinesterase inhibitors have minimal benefit and are cautioned related to the side effects and memantine proved also 
to have minimal benefit but less side effects (p. 462). An anti-depressant medication is also added to manage neuropsychiatric symptoms.  
Serotonin reuptake inhibitors, especially citalopram, have been helpful for agitation and paranoia (Press & Alexander, 2018). The primary 
health care provider enlists multi-disciplinary approach including nursing, pharmacy, physical/occupational therapy, dietary, and case 
management.  
Case Study
Reversible forms of dementia should be ruled out and treated before a diagnosis of Alzheimer’s disease is confirmed. More research is 
needed to determine how to slow down the inflammatory process and stop the deposits of beta-amyloid and tau proteins from forming.  
Lifestyle modifications to reduce the risk of vascular disease are important.  Prevention and proper management of arteriosclerosis, 
atherosclerosis, and diabetes could reduce the risk for developing dementia.
Age is considered the greatest contributing factor to dementia, but despite that, misconceptions exist that cognitive deficits are a 
normal part of aging (Stewart et al., 2014, p. 276).  Diagnosis is commonly made when a person is already moderately to severely affected 
by the disease, but early cognitive testing is an important aspect in diagnosis of dementia and might be beneficial if conducted prior to 
onset of obvious signs of impairment. Symptom management is crucial to try to preserve the patient’s quality of life, especially because no 
curative treatment is available.
Significance of Pathophysiology
• Nursing must consider the 
nonpharmacological approaches for 
dementia care, such as exercise and 
cognitive therapy.  
• Patient safety should be constantly 
assessed, and the environment 
modified as needed.  
• Education is very important for all the 
primary caregivers.  Dementia 
disease process and treatment 
options should be discussed with the 
patient and family.
• Encouragement of proper nutrition, 
sleep, elimination and management of 
chronic diseases, such as 
hypertension, diabetes, heart disease, 
etc. with medication compliance is an 
important part of care and may slow 
disease progression.
• Watching for side effects of treatment 
as well as changes in behavior and 
worsening cognitive function are 
essential parts of the assessment.
• The patient should be encouraged to 
perform or participate in all activities 
of daily living with a goal of 
maintaining independence for as long 
as possible.
• Advance directives and goals of care 
should be discussed with the patient 
and family.
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Clinical presentation is a gradual onset 
and involves impairment in cognition, 
language, and functional ability.
• Forgetfulness: chief complaint
• Difficulty retaining new information
• Unable to complete complex tasks
• Trouble with reasoning
• Disorientation, poor spatial ability
• Language impairment
• Behavioral disturbances (Larson, 
2019, p. 4-5)
Figure 3. World Health Organization, 2019.
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